Posted: April 19, 2022 at 1:53 am
POTOMAC, Md., April 18, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (OTC: ONOV) announces the closing of its acquisition of Lexington Solutions Group (“LSG”), a $4 million government contractor focused on information operations.
Original post:
Castellum, Inc. Closes on the Acquisition of Lexington Solutions Group
Posted: April 19, 2022 at 1:53 am
Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022
Continued here:
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
Posted: April 19, 2022 at 1:53 am
WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidney disease (CKD), preventing end-stage renal disease (ESRD), and preventing the need for dialysis. Social Capital Suvretta Holdings Corp. III (SCS) (Nasdaq: DNAC), is a special purpose acquisition company. ProKidney and SCS today announced that they will host an analyst and investor day in New York on Thursday, April 28, 2022, beginning at 8:00 a.m. ET.
Read the original:
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022
Posted: April 19, 2022 at 1:53 am
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases. The article titled, "Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study", is published in Modern Rheumatology and can be found here.
Link:
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
Posted: April 19, 2022 at 1:53 am
Distinguished neurosurgeon-inventor to lead continued development of Accelus’s Remi™ Robotic Navigation System Distinguished neurosurgeon-inventor to lead continued development of Accelus’s Remi™ Robotic Navigation System
Read more:
Accelus Appoints Kevin Foley, MD as Chief Robotics Officer
Posted: April 19, 2022 at 1:53 am
BIGS premium flower line and Hash-Wrapped Smoke are latest offerings from California’s No. 1 selling cannabis brand per Headset
Original post:
Lowell Herb Co. Expands Award-Winning Cannabis Brand with All-New Products
Posted: April 19, 2022 at 1:53 am
Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options
Posted: April 19, 2022 at 1:53 am
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
Go here to read the rest:
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Posted: April 19, 2022 at 1:53 am
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $125.0 million. The offering included new investors, Braidwell and Suvretta Capital Management’s Averill strategy, as well as participation from existing stockholders.
See the article here:
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
Posted: April 19, 2022 at 1:52 am
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21st at 11:30 a.m. ET.
Go here to see the original:
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
